- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02056301
A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair
June 1, 2020 updated by: Chris Glover, Baylor College of Medicine
A Comparison Trial Between Patient Controlled Intravenous Analgesia (PCA) and Epidural Analgesia for Pectus Excavatum Repair
The aim of this study is to compare the efficacy of epidural and IV analgesia in controlling pain in patients undergoing Nuss repair of pectus excavatum.
The primary end point will be the mean pain score during postoperative days 0-4.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Pectus excavatum is a cartilaginous deformity that is the most common congenital anterior chest wall defect in children [1].
Children with this disease process often complain of dyspnea, decreased exercise tolerance, and shortness of breath implying a restrictive pulmonary deficit [2].
Besides the reported physical limitations, patients can also exhibit manifestations of psychological disturbances (poor body image and depression).
Surgical repair has been correlated with enhanced quality of life and improvement in body image[3] with recent studies showing improved pulmonary function and cardiac output [4, 5].
Surgery initially introduced by Sauerbruch involved rib cartilage resection and sternal osteotomy.
This open procedure was further modified and became [6] known as the Ravitch procedure.
This was the mainstay for repair for over 40 years until the introduction of minimally invasive surgery without rib resection by Nuss and colleagues in 1987 [7].
The Nuss repair involves placing an intrathoracic brace through small lateral chest wall incisions aided by thoracoscopy.
Similar to bracing the teeth, the Nuss procedure avoids osteotomy or rib cartilage resection [8].
The Nuss procedure is the most common minimally invasive procedure in use today to correct this condition and is the current standard of surgical practice.
Complications from Nuss repair can range anywhere from 7% to 25% [9] and can occur for as long as the bar is in place.
Pain control remains a major issue in the perioperative period as patients may require weeks to months of oral narcotics before becoming pain-free after correction of the pectus.
A prospective multicenter study reported peak pain scores of 8 on a 0-10 scale in the postoperative period and a mean score of 3 at discharge [4].
Postoperative pain after pectus repair has been managed with IV opioids administered by patient controlled analgesia (PCA) devices and by thoracic epidural infusions of combinations of local anesthetics and opioids.
It is unclear from published data which method is superior and different tertiary care centers in the USA have a preference for different methods.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children't Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients age 8- 18 years 2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure 3) American Society of Anesthesiology Status I-III
Exclusion Criteria:
- 1) Refusal of epidural catheter 2) Pregnancy 3) Bleeding History 4) Inability to understand how to use the PCA device 5) Medication interfering with blood coagulation 6) Patients allergic to local anesthetics 7) Patient refusal to participate in study 8) Developmental delay
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Patient Controlled Analgesia
One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA).
This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
|
This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
|
Active Comparator: epidural Catheter
The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced.
This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
|
In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast.
In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Verbal Pain Scale Scores During Postoperative Days 0-4
Time Frame: Postoperative days 0-4
|
The aim of this study is to compare the efficacy of epidural and IV analgesia in controlling pain in patients undergoing Nuss repair of pectus excavatum.
The primary end point will be the mean pain scores during postoperative days (POD) 0-4.
Pain was measured using the verbal pain scale.
The scale ranges from 0-10.
A score of 0 means the patient is in no pain.
|
Postoperative days 0-4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Morphine Equivalent Consumption During Postoperative Days 0-4
Time Frame: Postoperative days 0-4
|
This outcome measures total amount of morphine administered in mg/kg by post-operative day 0-4.
This captures all standard of care opioids delivered via their assigned cohort route (Epidural vs. IV PCA).
Opioids other than morphine that were administered for pain were multiplied by their equianalgesic conversion factor to calculate the IV Morphine equivalent.
|
Postoperative days 0-4
|
Rescue Morphine Equivalent Administration During Postoperative Days 0-4
Time Frame: Postoperative days 0-4
|
This outcome measures the amount of rescue morphine administered due to breakthrough pain in mg/kg by post-operative day 0-4.
This captures additional opioids that were administered by a nurse through an IV.
Opioids other than morphine that were administered for pain were multiplied by their equianalgesic conversion factor to calculate the IV Morphine equivalent.
|
Postoperative days 0-4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chris Glover, MD, Baylor College of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
April 10, 2019
Study Completion (Actual)
October 1, 2019
Study Registration Dates
First Submitted
February 4, 2014
First Submitted That Met QC Criteria
February 4, 2014
First Posted (Estimate)
February 5, 2014
Study Record Updates
Last Update Posted (Actual)
June 11, 2020
Last Update Submitted That Met QC Criteria
June 1, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Congenital Abnormalities
- Musculoskeletal Diseases
- Bone Diseases
- Musculoskeletal Abnormalities
- Bone Diseases, Developmental
- Funnel Chest
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Morphine
- Hydromorphone
Other Study ID Numbers
- H31096
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pectus Excavatum
-
Galderma R&DPharma Consulting Group ABCompletedPectus Excavatum DeformityFrance, Sweden
-
Children's Health System, Inc.Walter Lorenz Surgical CorporationUnknownRepair of Pectus ExcavatumUnited States, Canada
-
Acibadem UniversityUnknownPhysical Disability | Psychosocial Impairment | Pectus DeformityTurkey
-
Zuyderland Medisch CentrumAtriCure, Inc.RecruitingFunnel Chest | Pectus ExcavatumNetherlands
-
Zuyderland Medisch CentrumUnknownPectus ExcavatumNetherlands
-
Medical University InnsbruckCompletedPectus Excavatum | Pectus CarinatumAustria
-
Johns Hopkins All Children's HospitalCompletedPectus ExcavatumUnited States
-
Zuyderland Medisch CentrumUnknown
-
Zuyderland Medisch CentrumUnknownPectus ExcavatumNetherlands
-
Centre Jean PerrinCompleted
Clinical Trials on Morphine
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Javelin PharmaceuticalsCompleted
-
Javelin PharmaceuticalsCompletedPain, PostoperativeUnited States
-
University of MonastirCompletedTitrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings (TIMORNEB)Acute Pain | Post-Traumatic HeadacheTunisia
-
Mahidol UniversityCompletedLung Diseases | Solitary MassThailand
-
University of Colorado, DenverCompletedScoliosis | Pain Management | Spinal FusionUnited States
-
Javelin PharmaceuticalsCompletedPost-Operative Pain | Third Molar Extraction
-
Cukurova UniversityCompleted
-
University College Hospital GalwayCompletedPain, Postoperative | Arthroplasty, Replacement, Knee
-
Rijnstate HospitalCompletedTotal Hip Replacement